NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
241 Kronoberg |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 38 | 1.0% | 1 | 0.0% | 5 | 0.1% | . | . | . | . | . | . | 3773 | 98.8% | 3817 | 100.0% |
ASCUS | 82 | 36.3% | 26 | 11.5% | 37 | 16.4% | 1 | 0.4% | . | . | 2 | 0.9% | 78 | 34.5% | 226 | 100.0% |
LSIL | 30 | 28.3% | 19 | 17.9% | 18 | 17.0% | . | . | . | . | 2 | 1.9% | 37 | 34.9% | 106 | 100.0% |
Atypical glandular cells/AGC | 1 | 33.3% | . | . | . | . | 1 | 33.3% | 1 | 33.3% | . | . | . | . | 3 | 100.0% |
Unclear atypia | 4 | 23.5% | 2 | 11.8% | 9 | 52.9% | 2 | 11.8% | . | . | . | . | . | . | 17 | 100.0% |
ASC-H | 11 | 21.6% | 4 | 7.8% | 36 | 70.6% | . | . | . | . | . | . | . | . | 51 | 100.0% |
HSIL | 2 | 5.3% | 4 | 10.5% | 31 | 81.6% | . | . | . | . | 1 | 2.6% | . | . | 38 | 100.0% |
Suspected Adenocarcinom | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | 1 | 100.0% |
Totalt | 168 | 3.9% | 56 | 1.3% | 136 | 3.2% | 5 | 0.1% | 1 | 0.0% | 5 | 0.1% | 3888 | 91.3% | 4259 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M81403 |